HPLC · CoA
BPC-157 vs TB-500: What Is the Difference?
Comparison · 7 min read · Updated 30 September 2026
The difference between BPC-157 and TB-500 is that they are unrelated molecules: BPC-157 is a synthetic 15 amino acid peptide of about 1,419 Da derived from a gastric juice protein, while TB-500 is synthetic material based on thymosin beta 4, a 43 residue actin-sequestering protein of about 4,963 Da. BPC-157 is studied mainly for VEGFR2, focal adhesion kinase and nitric oxide signalling; thymosin beta 4 for actin dynamics and cell migration. They share no sequence and act through separate pathways.
We supply both as single vials, as a co-lyophilised blend and as a two-vial set, so the practical BPC-157 vs TB-500 decision is which format suits a given experimental design. That decision starts with the molecular profile of each compound.
BPC-157 vs TB-500 at a Glance
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Chain length | 15 amino acids | 43 amino acids in full thymosin beta 4 |
| Molecular weight | About 1,419 Da | About 4,963 Da for the full chain |
| Origin | Copied from part of a gastric juice protein | Thymosin beta 4, first sequenced from calf thymus in 1981 |
| N-terminal cap | None | Acetyl group |
| Main research focus | VEGFR2, FAK and paxillin signalling, the nitric oxide system | G-actin sequestration, cell migration, integrin-linked kinase |
| Typical models | Tendon fibroblasts, gut lining, vessel formation assays | Cytoskeleton studies, dermal and cardiac models |
| Sizes we stock | 5mg and 10mg | 2mg, 5mg and 10mg |
What Is BPC-157?
BPC-157 is a synthetic pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, taken from a larger body protection compound isolated from gastric secretions in the early 1990s. A run of three prolines near the N-terminus gives it an unusually rigid backbone for so short a chain, and reports describe it remaining intact at a low pH that would fragment most chains of similar length.
Mechanistic work concentrates on signalling. A 2011 Journal of Applied Physiology study in tendon fibroblasts linked the peptide to the focal adhesion kinase and paxillin pathway, which governs cell adhesion and spreading. A 2017 Journal of Molecular Medicine study in endothelial cells reported VEGFR2 activation, an early step in new vessel formation, and many rodent studies examine its interaction with the nitric oxide system. A pharmacokinetic study in rats and dogs, published in Frontiers in Pharmacology in 2022, reported a short plasma half-life for the intact peptide. The published record is collected in our BPC-157 research library, and we supply lyophilised BPC-157 in two strengths.
What Is TB-500?
TB-500 is the research-market name for synthetic material based on thymosin beta 4, a 43 residue protein with an acetylated N-terminus that is present in nearly every mammalian cell and abundant in platelets. Within the cell it regulates the actin pool: monomeric G-actin is bound one to one and held back from filament assembly until required, which makes the protein a determinant of cell shape and motility. A 1991 Journal of Biological Chemistry report identified it with Fx, an actin-sequestering peptide first isolated from platelets, and binding depends on the central motif LKKTETQ.
Some suppliers apply the name to the full chain and others to a short fragment built around the actin-binding motif, so the certificate for each lot of our TB-500 vials states which form is present. The best-known studies, a 1999 rat dermal model in the Journal of Investigative Dermatology and a 2004 Nature paper linking the protein to integrin-linked kinase in cardiac cells, used the full-length molecule.
How Do BPC-157 and TB-500 Differ in Structure and Mechanism?
BPC-157 and TB-500 differ in size, in where they act and in the research questions each is used to address, which is why they are usually treated as separate experimental variables.
Size and Structure
At roughly 1.4 kDa, BPC-157 has under a third of the mass of full thymosin beta 4. A shorter chain is simpler to synthesise and to verify by mass spectrometry. A longer one presents more sites for oxidation and cleavage, and the methionine at position 6 of thymosin beta 4 is a recognised oxidation point, one reason that material is best kept cold and dry until reconstitution.
Site of Action
BPC-157 studies centre on signalling at and around the cell surface, with VEGFR2 and focal adhesion kinase the recurring targets. Thymosin beta 4 acts largely inside the cell on the actin pool, although extracellular roles have also been reported in migration assays.
Research Applications
Laboratories select BPC-157 for vessel formation, tendon cell and gut lining models, and thymosin beta 4 when the question concerns cytoskeletal dynamics, cell migration or the actin cycle. Because both appear in tissue repair models through different routes, they are often run as parallel arms. Reported half-lives for each are compared in our post on peptide half-life.
Can BPC-157 and TB-500 Be Combined in One Vial?
Yes, BPC-157 and TB-500 can be combined in one vial, and they are manufactured as a co-lyophilised pair because both are water-soluble and reconstitute in preserved diluent for peptide stocks. The substantive question is experimental design, and there are three ways to set it up.
| Setup | What you get | Advantage | Limitation |
|---|---|---|---|
| Two separate vials | Independent stocks, lots and certificates | Single-compound control arms and any ratio | Two reconstitutions and two labels |
| Pre-blended vial | Fixed 1:1 pair in one freeze-dried cake | One reconstitution, fewer punctures | Ratio is fixed and single arms need extra vials |
| Two stocks combined by hand | A mixed solution made at the bench | Custom ratio | Dilutes both, merges lots, harder to document |
For separate vials, the recovery stack of two 10mg vials supplies one of each under its own lot number. For a single reconstitution, the BPC-157 and TB-500 blend in 5+5mg or 10+10mg holds equal amounts of both. Adding 2 mL to the 10+10mg vial gives 10 mg per mL combined, half of it each compound, so one U-100 unit carries 50 mcg of each.
Combining stocks by hand is also possible, but the arithmetic changes. Each solution dilutes the other, so equal 1 mL portions of two stocks each prepared at 5 mg per mL combine into 2 mL holding 2.5 mg per mL of each. Both lot numbers belong on the new vial.
Should a Study Use a Single Compound or the Pair?
A study should use single-compound vials whenever an observed effect must be attributed to one molecule, and add the pair only when the combination itself is the subject. A design comparing each peptide alone with both together has three arms, so it requires single vials as well as the combination.
Our recommendation: where a study will ever need to state which compound produced which effect, begin with separate vials and add the blend only when the fixed 1:1 pair is itself under test. Neighbouring compounds for the same models sit in our recovery research peptides, and the regulatory position is set out in how these peptides are regulated in Australia.
Questions about BPC-157 vs TB-500
Sources
- Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. 1991.
- Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004.
- Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017.
Written by the Macropus Peptides technical team for in-vitro laboratory research reference. Not medical advice; products are not for human or veterinary use and are sold to buyers aged 18 and over.